Engimmune Therapeutics raised €15M in a Seed round in May 2022. The company is based in Basel, Switzerland. Investors in the round: Novo Holdings, Pureos Bioventures. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
